LifeMD (LFMD) Stock Forecast: StockMap's 2-Week Call

LFMD stock forecast: StockMap's model leans Underperform on LifeMD for the two weeks after the Nov 19 close, toward LFMD trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 4 of 6 two-week windows on LFMD since Aug 21; by chance, a call on the same dates was right 59% of the time.

LifeMD last closed at $1.59, -6.47% on the session.

Against the IVW growth benchmark the position is -4.14% over the forecast window.

LifeMD's market cap is $76.85M as of November 19, 2026.

Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -33 (too close to call).

Where LFMD sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

49 daily calls for LFMD so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks LifeMD in the 4th percentile on return on equity, where 100 is best.

LifeMD is classified under Health Care / Health Care Technology.

StockMap tracks LifeMD as the 18th largest of the 21 companies it covers in the Health Care Technology industry, part of the Health Care sector.

Across that group the current two-week reads are 15 Neutral, 3 Moderate Underperform and 3 Strong Underperform.

On that composite LifeMD ranks 18th of 21 in the group, against a group median of -0.01.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

LifeMD (LFMD) — StockMap 2-week forecast & tracked accuracy